Fight for Biosite continues as Beckman ups bid to challenge IMI (Inverness Medical Innovations) head to head:
This article was originally published in Clinica
Executive Summary
Beckman Coulter this week opened the scene for an all-out bidding war after raising its bid for diagnostics developer Biosite to match the offer of its rival Inverness Medical Innovations (IMI). Beckman and Biosite had entered a merger agreement on March 24, in which the former would buy all outstanding Biosite stock in a cash tender offer for $85 per share. Days later IMI had come in with a higher offer of $90 per share, which Biosite said it will consider. As Beckman's cash tender offer was set to expire last week, there had been no indication from any of the players as to how the story would end. However, Fullerton, California-based Beckman has now upped its bid for Biosite to the same price with which IMI had hoped to entice the latter. As Clinica went to press, neither Biosite or IMI were available for comment.
You may also be interested in...
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.